{"retracted":false,"update":{"timestamp":1483228800000,"doi":"10.1016/j.ejca.2016.11.001","type":"erratum"},"doi":"10.1016/j.ejca.2016.03.068","journal":"European Journal of Cancer","publisher":"Elsevier BV","title":"Corrigendum to ‘Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models’ [Eur J Cancer 61 (2016) 20–28]"}
